natgillin/translations-raw huggingface dataset:
Type III amber glass bottles with polypropylene child-resistant closures and a desiccant, containing 5 or 20 capsules.
Bočice od žutog stakla tipa III, s polipropilenskim sigurnosnim zatvaračima za djecu i sredstvom za sušenje, koje sadrže 5 ili 20 kapsula.
Type III amber glass bottles with white polypropylene child-resistant closure with desiccant.
Bočicama od smeđeg stakla tipa III, s bijelim polipropilenskim sigurnosnim zatvaračem za djecu i sredstvom za sušenje.
Type III brown glass bottle with screw cap of HDPE and LDPE seal.
Smeđa staklena boca tipa III s poklopcem na odvijanje od HDPE i zaštitnim zatvaračem od LDPE.
Type III glass bottle with high density polyethylene tamper evidence screw cap.
Bočica od stakla tipa III sa sigurnosnim navojnim zatvaračem od polietilena visoke gustoće.
Type of Bleeding
Vrsta krvarenja
Type of event, n (%)
Vrsta događaja, n (%)
Type of infection
Vrsta infekcije Doza
Type of Plasma Intervention
Vrsta intervencije koja uključuje plazmu
Type of rash, characterised by appearance of a flat, red area on the skin covered with bumps (maculo-papular rash)
Vrsta osipa kojeg karakterizira pojava plosnatog, crvenog područja na koži prekrivenog kvržicama (makulopapularni osip)
Type of skin impairment
Oblik oštećenja kože
Type-2 diabetes is a disease in which the body does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Dijabetes tipa 2 je bolest kod koje tijelo ne stvara dovoljno inzulina kako bi kontroliralo razinu glukoze u krvi ili kada tijelo nije u stanju učinkovito koristiti inzulin.
Type-I glass pre-filled syringe containing powder in the front chamber and solvent in the rear chamber.
Napunjena štrcaljka od stakla tipa I s dvije komore od kojih prednja komora sadrži prašak, a stražnja otapalo.
Type-I glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.
Bočica od stakla tipa I začepljena čepom od laminirane gume i zatvorena aluminijskim poklopcem.
Type2 diabetes mellitus
Šećerna bolest tipa 2
Types of IPD(1)
Tipovi IPB-a(1)
Types of skin cancers (basal cell carcinoma, new primary melanoma)
vrste raka kože (karcinom bazalnih stanica, novi primarni melanom)
Typical adverse drug reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Uobičajene nuspojave nesteroidnih antiinflamatornih (protuupalnih) lijekova (NSAIL) poput gubitka apetita, povraćanja, proljeva, krvi u stolici, apatije i zatajenja bubrega povremeno su prijavljene.
Typical adverse drug reactions of non-steroidal anti-inflammatory drugs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSAID) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, letargije i zatajenja bubrega.
Typical adverse drug reactions of non-steroidal anti-inflammatory drugs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSPUL) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, letargije i zatajenja bubrega.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported.
Povremeno se mogu javiti nuspojave karakteristične za nesteroidne protuupalne lijekove (NSPUL), poput gubitka apetita, povraćanja, proljeva, pojave krvi u izmetu te apatije.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Povremeno su zabilježene tipične nuspojave nesteroidnih protuupalnih lijekova kao što su gubitak apetita, povraćanje, proljev, okultno krvarenje u stolici, apatija i zatajenje bubrega.
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Uobičajene nuspojave nesteroidnih antiinflamatornih (protuupalnih) lijekova (NSAIL) poput gubitka apetita, povraćanja, proljeva, krvi u stolici, apatije i zatajenja bubrega povremeno su prijavljene.
Typical adverse drug reactions of NSAIDS such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Uobičajene nuspojave nesteroidnih antiinflamatornih (protuupalnih) lijekova (NSAIL) poput gubitka apetita, povraćanja, proljeva, krvi u stolici, apatije i zatajenja bubrega povremeno su zabilježene.
Typical adverse reactions of Non Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Povremeno se mogu javiti nuspojave karakteristične za NSPUL, poput gubitka apetita, povraćanja, proljeva, pojave krvi u izmetu,apatije i zatajenja bubrega.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood lethargy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSAID) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, letargije i zatajenja bubrega.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Povremeno se mogu javiti nuspojave karakteristične za NSPUL, poput gubitka apetita, povraćanja, proljeva, pojave krvi u izmetu te apatije.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Uobičajene nuspojave nesteroidnih antiinflamatornih (protuupalnih) lijekova (NSAIL) poput gubitka apetita, povraćanja, proljeva, krvi u stolici, apatije i zatajenja bubrega povremeno su prijavljene.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Uobičajene nuspojave nesteroidnih antiinflamatornih (protuupalnih) lijekova (NSAIL) poput gubitka apetita, povraćanja, proljeva, krvi u stolici, apatije i zatajenja bubrega povremeno su zabilježene.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure, have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSAID) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, letargije i zatajenja bubrega.
Typical adverse reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSAID) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu letargije i zatajenja bubrega.
Typical adverse reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSAID) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, letargije i zatajenja bubrega.
Typical adverse reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSAID) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u stolici, letargije i zatajenja bubrega.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Prijavljene su povremene tipične nuspojave NSAID-a kao što su gubitak teka, povraćanje, dijareja, nevidljivo postojanje krvi u stolici, letargija i zatajenje bubrega.
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure, have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSPUL) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, letargije i zatajenja bubrega.
Typical adverse reactions of non-steroidal anti-inflammatory drugs NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Uobičajene nuspojave nesteroidnih antiinflamatornih (protuupalnih) lijekova (NSAIL) poput gubitka apetita, povraćanja, proljeva, krvi u stolici, apatije i zatajenja bubrega povremeno su zabilježene.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Povremeno se mogu javiti nuspojave karakteristične za NSPUL, poput gubitka apetita, povraćanja, proljeva, pojave krvi u izmetu te apatije.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSPUL) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, apatija i zatajenja bubrega.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSPUL) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, apatije i zatajenja bubrega.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Uobičajene nuspojave nesteroidnih antiinflamatornih (protuupalnih) lijekova (NSAIL) poput gubitka apetita, povraćanja, proljeva, krvi u stolici, apatije i zatajenja bubrega povremeno su prijavljene.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Uobičajene nuspojave nesteroidnih antiinflamatornih (protuupalnih) lijekova (NSAIL) poput gubitka apetita, povraćanja, proljeva, krvi u stolici, apatije i zatajenja bubrega povremeno su zabilježene.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSAID) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, letargije i zatajenja bubrega.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSAID) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u stolici, letargije i zatajenja bubrega.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Povremeno su zabilježene nuspojave karakteristične za nesteroidne protuupalne lijekove (NSPUL) poput gubitka apetita, povraćanja, proljeva, okultnog krvarenja u izmetu, letargije i zatajenja bubrega.
Typical appearance of a person with high levels of steroids, such as moon face, hump back, upper body obesity
Tipičan izgled osobe s visokim razinama steroida, kao što je mjesečasto lice, bivolja grba, debljina u gornjem dijelu tijela
Typical courses of treatment are given below.
Tipično trajanje ciklusa navedeno je u nastavku.
Typical doses are given below.
Uobičajene doze su navedene u nastavku.
Typical opioid adverse ractions are to be expected with Effentora.
Kod Effentore treba očekivati tipične nuspojave opioida.
Typical opioid are to be expected with Effentora.
Kod Effentore treba očekivati tipične nuspojave opioida.
Typical signs of anxiety and fear are panting, trembling, pacing (frequent change of place, running around, restlessness), seeking people (clinging, hiding behind, pawing, following), hiding (under furniture, in dark rooms), trying to escape, freezing (absence of movements), refusing to eat food or treats, inappropriate urination, inappropriate defecation, salivation, etc.
Tipični znakovi anksioznosti i straha su dahtanje, drhtanje, šetkanje (učestalo mijenjanje mjesta, trčkaranje, nemir), traženje ljudi (hvatanje, sakrivanje iza njih, grebanje šapom, praćenje), sakrivanje (ispod namještaja, u mračne prostorije), bježanje, nepokretnost. (izostanak pokreta), odbijanje hrane ili poslastica, inkontinencija, defekacija, slinjenje itd.
Typical symptoms are: swelling of the face, lips, mouth, tongue and/or throat, which may cause difficulty in swallowing or breathing, hives (nettle rash), severe dizziness with very fast heartbeat and heavy sweating.
Tipični simptomi su: oticanje lica, usana, usta, jezika i/ili grla, što može uzrokovati teškoće pri gutanju ili disanju, koprivnjača (urtikarija), jaka omaglica s vrlo brzim otkucajima srca i izrazitim znojenjem.
Typically cytoreductive therapy is considered in high risk paediatric patients.
U visokorizičnih pedijatrijskih bolesnika obično se razmotri provedba citoredukcijske terapije.
Typically, laboratory observations of proteinuria were not progressive.
Tipično, proteinurije opažene u laboratorijskim testovima nisu bile progresivne.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Takve su reakcije tipično zapaţene unutar prvih nekoliko tjedana ili mjeseci po uvoĎenju CART-a.
Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Takve su reakcije tipično zapažene unutar prvih nekoliko tjedana ili mjeseci po uvoĎenju CART-a.
Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may be become more brownish.
Tipično je da se smeđa pigmentacija oko zjenice širi koncentrično prema periferiji oboljelog oka, ali cijela šarenica ili njezini dijelovi mogu postati više smeđi.
Typically, your child should receive receive an initial course of three injections followed by a booster dose
Obično će Vaše dijete primiti početni niz od tri injekcije, a nakon njih dozu za docjepljivanje.
Tyramine/safinamide interaction
Interakcija tiramin/safinamid
TYSABRI 300 mg is administered by intravenous infusion once every 4 weeks.
TYSABRI 300 mg primjenjuje se u obliku intravenske infuzije svaka 4 tjedna.
Tysabri has been investigated in two studies, both lasting two years.
Lijek Tysabri ispitivan je u okviru dvaju dvogodišnjih ispitivanja.
Tysabri is a concentrate that is made up into a solution for infusion (drip) into a vein.
Tysabri je koncentrat od kojeg se priprema otopina za intravensku infuziju (drip).
TYSABRI is contraindicated in combination with beta-interferons or glatiramer acetate (see section 4.3).
TYSABRI je kontraindiciran u kombinaciji s interferonima beta ili glatiramer acetatom (vidjeti dio 4.3).
Tysabri is given as a one-hour infusion every four weeks.
Lijek Tysabri daje se u obliku jednosatne infuzije svaka četiri tjedna.
TYSABRI is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:
TYSABRI je indiciran kao imunomodulacijska monoterapija za visoko aktivnu relapsno-remitentnu multiplu sklerozu kod sljedećih skupina odraslih bolesnika:
Tysabri is used in the type of MS known as ‘relapsing-remitting’ MS, when the patient has attacks (relapses) in between periods with no symptoms (remissions).
Lijek Tysabri upotrebljava se za liječenje bolesnika s vrstom multiple skleroze poznate pod nazivom „relapsno- remitentna”, pri kojoj bolesnik ima napadaje (relapse) između razdoblja bez simptoma (remisija).
Tysabri is used to treat adults with highly active multiple sclerosis (MS).
Lijek Tysabri primjenjuje se u liječenju odraslih s visokoaktivnom multiplom sklerozom (MS).
TYSABRI must be diluted before it is given to you.
TYSABRI se mora razrijediti prije primjene.
Tysabri must not be given to patients who have PML or who are at risk of getting an infection, including patients whose immune systems are weakened.
Lijek Tysabri ne smije se primjenjivati u bolesnika s PML-om ili u bolesnika koji su izloženi riziku od dobivanja upale, uključujući bolesnike s oslabljenim imunosnim sustavom.
TYSABRI must not be mixed with other medicinal products or diluents.
TYSABRI se ne smije miješati s drugim lijekovima ili otapalima.
Tysabri used on its own was more effective than placebo in reducing the number of relapses.
Kao monoterapija, lijek Tysabri bio je učinkovitiji u smanjenju broja relapsa od placeba.
Tysabri was also more effective than placebo on the disabling effects of MS: over two years, the risk of disability getting worse was reduced by 42% in comparison with placebo.
U razdoblju od dvije godine rizik od pogoršanja invaliditeta smanjio se za 42 % u usporedbi s placebom.
Tyverb (1,250 mg/day)+ capecitabine (2,000 mg/m2/day, days 1-14 q21 days)
Tyverb (1250 mg/dan) + kapecitabin(2000 mg/m2/dan, 1.-14. dan, ciklus od 21 dan)
Tyverb / aromatase inhibitor combination posology
Doziranje kombinacije Tyverb/inhibitor aromataze
Tyverb / capecitabine combination posology
Doziranje kombinacije Tyverb/kapecitabin
Tyverb / capecitabine combination posology
Doziranje pri kombinaciji Tyverb / kapecitabin
Tyverb 1500 mg
Tyverb 1500 mg/dan
Tyverb in combination with another cancer medicine was more effective than the comparator treatment in all studies.
Tyverb u kombinaciji s drugim lijekom protiv raka bio je djelotvorniji od komparatorske terapije u svim ispitivanjima.
Tyverb is a cancer medicine that contains the active substance lapatinib.
Tyverb je lijek protiv karcinoma koji sadrži djelatnu tvar lapatinib.
Tyverb is also available in plastic bottles containing 70, 84, 105 or 140 tablets.
Tyverb je dostupan i u plastičnim bočicama koje sadrže 70, 84, 105 ili 140 tableta.
Tyverb is also supplied in high density polyethylene bottles (HDPE) with a child resistant polypropylene closure containing 70, 84, 105 or 140 film-coated tablets.
Tyverb je dostupan i u bočicama od polietilena visoke gustoće (HDPE) s poliproplilenskim sigurnosnim zatvaračem za djecu koje sadrže 70, 84, 105 ili 140 filmom obloženih tableta.
Tyverb is not indicated in the adjuvant setting.
Tyverb nije indiciran za adjuvantno liječenje.
Tyverb is prescribed in combination with trastuzumab, for patients who have hormone receptor- negative metastatic breast cancer and have had other treatment for advanced or metastatic breast cancer before.
Tyverb se propisuje u kombinaciji s trastuzumabom, za bolesnike s metastatskim rakom dojke negativnim na hormonske receptore koji su prethodno liječeni drugim lijekovima za uznapredovali ili metastatski rak dojke.
Tyverb is supplied in either blister packs or bottles.
Tyverb je dostupan u blisterima ili bočicama.
Tyverb is supplied in either blisters packs or bottles:
Tyverb je dostupan u blisterima ili u bočicama:
Tyverb is used to treat patients with breast cancer that has been shown to be ‘expressing’ large amounts of HER2.
Tyverb je indiciran u liječenju odraslih bolesnika s karcinomom dojke čiji tumori pokazuju prekomjernu ekspresiju HER2.
Tyverb should only be started by a doctor who has experience in giving cancer medicines.
Liječenje lijekom Tyverb smije započeti isključivo liječnik s iskustvom u primjeni antineoplastičnih lijekova.
Tyverb was originally given ‘conditional approval’.
Za lijek Tyverb je prvotno izdano „uvjetno odobrenje”.
Tyverb was studied in three main studies involving women with breast cancer.
Tyverb je ispitan u tri glavna ispitivanja koja su obuhvatila žene s karcinomom dojke.
Tyverb-induced diarrhoea is usually low- grade, with severe diarrhoea of NCI CTCAE grades 3 and 4 occurring in <10% and <1% of patients, respectively.
Proljev izazvan lijekom Tyverb najčešće je niskog stupnja, dok se teški proljev 3. ili 4. stupnja prema NCI CTCAE pojavljuje u < 10%, odnosno <1% bolesnika.
t½, hours
t½, sati
Táncsics Mihály út 82 Hungary
Táncsics Mihály út 82 Mađarska
Tél (N° vert): +33-(0)800 87 54 54
Tél: (N° vert): +33-(0)800 87 54 54
Tél.: + 33 (0)1 39 17 84 44 diam@gsk.com
Laboratoire GlaxoSmithKline Tél. : + 33 (0)1 39 17 84 44 diam@gsk.com
Tél/Tel: + 32 (0)10 85 52 00
Tél/Tel : + 32 (0) 10 85 52 00
Tél/Tel: + 32 (0)10 85 52 00
Tél/Tel : + 32 (0)10 85 52 00
Tél/Tel: + 32 02 658 61 00 (Belgique/Belgien)
Tél/Tel: +32 02 658 61 00 (Belgique/Belgien)
Tél/Tel: + 32 10 85 52 00
Тел. + 359 2 953 10 34 Tél/Tel: + 32 10 85 52 00
Tél/Tel: +32 (0) 2 525 82 11
Tél/Tel: +32 (0) 2 525 82 11 Tel: +370 5 2546799
Tél/Tel: +32 (0) 489 304 091 (BE)
Teл.: + 359 (02) 962 34 50 Tél/Tel: +32 (0) 489 304 091 (BE)
Tél/Tel: +32 10 477811
Tél/Tel: + 32 10 477811
Tél/Tel: 0800 38 693 (+32(0)27766211) dpoc_belux@merck.com
Tél/Tel: 0800 38 693 (+32 (0)27766211) dpoc_belux@merck.com
Tél: + 33 (0) 1 80 46 40 40
Tél: 33 (0) 1 80 46 40 40
Tél: +33 (0) 1 45 60 13 00
Tél: + 33 (0) 1 45 60 13 00
Tél: +33 (0)1 45 60 13 00
Tél: +33 (0) 1 45 60 13 00
Tél: +33 (0)1 47 61 40 00
Tél: +33 (0) 1 46 40 50 00
Tél: +33 (0)1 47 73 64 58
Tél. : +33 1 47 73 64 58
Tél: +33 (0)1 47 73 64 58 Tel: +34 91 659 28 90
Tel : +34 93 342 51 20
Tél: +33 (0)1 58 07 34 40 Tel: +40 (0)21 207 28 00
Tél: +33 (0)1 58 07 34 40 Tel: +351 21 423 5500
Tél: +33 1 55 91 7800
Tél: +(33) 1 55 91 7800
Tél: +33 4 72 72 60 72
Tél: + 33 4 72 72 60 72
Tél: +33 810 421 000 infotherapies@linde.com
Tel: + 351 218 310 420 linde.portugal@pt.linde-gas.com
Tél: +33-(0) 1 55 49 34 34
Tél: +33-(0)1 55 49 34 34
UA/NQMI: For a patient who weighs  70 kg, it is recommended that a bolus dose of 5,000 units is given, followed by a constant intravenous infusion of 1,000 units/hr.
Nestabilna angina ili non Q infarkt miokarda: Za bolesnika koji teži  70 kg preporučuje se primjena bolus doze od 5000,00 jedinica, nakon koje treba uslijediti intravenska infuzija od 1000 jedinica/h.
UAB Merck Sharp & Dohme Tel.: +370 5 278 02 47 msd_lietuva@merck.com
UAB Merck Sharp & Dohme Tel.: +378 5 278 02 47 msd_lietuva@merck.com
UAB Sicor Biotech filiāle Latvijā
UAB Sicor Biotech filiāle Latvija
UAB Sicor Biotech filiāle Latvijā Tel: +371 67 323 666
UAB Sicor Biotech filiāle Latvijā
UAB «SANOFI-AVENTIS LIETUVA» Tel: +370 5 2755224
UAB « SANOFI-AVENTIS LIETUVA » Tel: +370 5 2755224
UAB “Actavis Baltics” Latvijas filiāle Tel: +371 67304300
UAB “Actavis Baltics” Latvijas filiāle Tel: +371 67 304300
UAB “Actavis Baltics” Latvijas filiāle Tel: +371 67304300
UAB “Actavis” Latvijas filiāle Tel: +371 67304300
UAB “JOHNSON & JOHNSON” filiāle Latvijā Tel: +371 6789 3561
Janssen-Cilag Polska Sp. z o.o. filiāle Latvijā Tel: +371 6789 3561
UAB “SANOFI-AVENTIS LIETUVA” Tel: +370 5 2755224
UAB “SANOFI-AVENTIS LIETUVA“ Tel: +370 5 2755224
UAB “Sicor Biotech” filiāle Latvijā Tel: +371 673 23 666
UAB "Sicor Biotech" filiāle Latvijā Tel: +371 673 23 666
UAB “Sicor Biotech” Latvian Affiliate Telephone: +371 67784980
Telephone: +(421) 2 5726 7911
UAB „SANOFI-AVENTIS LIETUVA“ Tel: +370 5 2755224
UAB „SANOFI_AVENTIS LIETUVA“ Tel: +370 5 2755224
UAbsorption
UApsorpcija
UAdults
Odrasli
ub-cutaneous tissue disorders
i potkožnog tkiva